By TOM MURPHY

Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition.

Related Articles

Sustainable wine bar to open in Gaithersburg

A jury will look at whether Amazon tricked customers into joining Prime — and made it hard to leave

Columbia named the best city for women to live in

Seattle, a coffee haven, is watching java prices spike. Why?

Spirit Airlines to furlough 1,800 flight attendants amid second bankruptcy

The COVID-19 vaccine and treatment maker said Monday that it will pay $47.50 in cash for each share of development-stage drugmaker Metsera. That represents a premium of more than 42% to Metsera’s closing price Friday.

Pfizer also could pay an additional $22.5

See Full Page